Restructuring and Other Costs (Income), Net (Tables)

12 Months Ended

Dec. 31, 2014

Restructuring And Other Costs, Net Disclosure

Schedule of Restructuring and Related Costs [Table Text Block]

2014

During 2014, the company recorded net restructuring and other costs (income) by segment as follows:

(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs (Income), Net		Total
Life Sciences Solutions	$	327.3	$	122.5	$	(516.4)	$	(66.6)
Analytical Instruments		(0.8)		0.9		2.5		2.6
Specialty Diagnostics		0.9		1.5		17.7		20.1
Laboratory Products and Services		0.2		—		(121.0)		(120.8)
Corporate		—		5.8		19.0		24.8
	$	327.6	$	130.7	$	(598.2)	$	(139.9)

During 2013, the company recorded net restructuring and other costs as follows:

(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs, Net		Total
Life Sciences Solutions	$	—	$	51.7	$	4.4	$	56.1
Analytical Instruments		2.9		0.6		20.9		24.4
Specialty Diagnostics		24.9		12.9		24.2		62.0
Laboratory Products and Services		0.8		—		25.2		26.0
Corporate		—		8.3		3.0		11.3
	$	28.6	$	73.5	$	77.7	$	179.8

During 2012, the company recorded net restructuring and other costs as follows:

(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs, Net		Total
Life Sciences Solutions	$	0.7	$	—	$	7.8	$	8.5
Analytical Instruments		0.4		(0.1)		32.8		33.1
Specialty Diagnostics		52.8		13.7		15.0		81.5
Laboratory Products and Services		1.7		(0.9)		25.5		26.3
Corporate		—		(0.2)		1.0		0.8
	$	55.6	$	12.5	$	82.1	$	150.2

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.

				Abandonment
(In millions)		Severance			of Excess Facilities		Other (a)		Total
Pre-2013 Restructuring Plans
	Balance At December 31, 2011	$	17.8		$	7.2	$	2.6	$	27.6
	Costs incurred in 2012 (c)		46.3			13.3		9.2		68.8
	Reserves reversed (b)		(1.6)			—		(0.6)		(2.2)
	Payments		(42.8)			(12.3)		(8.4)		(63.5)
	Currency translation		0.3			0.1		—		0.4
	Balance At December 31, 2012		20.0			8.3		2.8		31.1
	Costs incurred in 2013		9.4			7.1		3.1		19.6
	Reserves reversed (b)		(2.6)			(0.1)		(0.3)		(3.0)
	Payments		(20.3)			(7.3)		(5.3)		(32.9)
	Currency translation		0.1			—		—		0.1
	Balance At December 31, 2013		6.6			8.0		0.3		14.9
	Costs incurred in 2014 (d)		0.5			2.4		—		2.9
	Reserves reversed (b)		(1.8)			(0.1)		(0.1)		(2.0)
	Payments		(3.3)			(4.1)		(0.1)		(7.5)
	Currency translation		(0.3)			0.4		—		0.1
	Balance At December 31, 2014	$	1.7		$	6.6	$	0.1	$	8.4
2013 Restructuring Plans
	Costs incurred in 2013	$	48.3		$	3.2	$	9.9	$	61.4
	Payments		(26.7)			(1.8)		(7.7)		(36.2)
	Currency translation		0.4			—		—		0.4
	Balance At December 31, 2013		22.0			1.4		2.2		25.6
	Costs incurred in 2014 (d)		6.7			1.7		10.4		18.8
	Reserves reversed (b)		(3.7)			—		(0.1)		(3.8)
	Payments		(20.0)			(2.2)		(10.2)		(32.4)
	Currency translation		(0.5)			—		(0.6)		(1.1)
	Balance At December 31, 2014	$	4.5		$	0.9	$	1.7	$	7.1
2014 Restructuring Plans
	Costs incurred in 2014 (d)	$	133.6		$	6.4	$	92.0	$	232.0
	Payments		(100.8)			(4.1)		(87.8)		(192.7)
	Currency translation		(1.3)			—		(0.1)		(1.4)
	Balance At December 31, 2014	$	31.5		$	2.3	$	4.1	$	37.9

(a)Other includes cash charges to monetize certain equity awards held by employees of Life Technologies at the date of acquisition, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

(b) Represents reductions in cost of plans.

(c) Excludes an aggregate of $15 million of non-cash charges, net, which are detailed by segment above.

(d) Excludes a $895.4 million net gain on the sale of businesses, principally the company’s sera and media, gene modulation and magnetic beads businesses and the Cole-Parmer business; $19.6 million of cash compensation to monetize certain equity awards held by Life Technologies’ employees at the date of acquisition that was paid by Life Technologies prior to the acquisition; $9.3 million of provision for losses on pre-acquisition litigation-related matters of Life Technologies; and an aggregate of $19.9 million of non-cash charges, net.

The company expects to pay accrued restructuring costs as follows: severance, employee-retention obligations and other costs, primarily through 2015; and abandoned-facility payments, over lease terms expiring through 2020.